Tackle Prostate Cancer
Tackle Prostate Cancer – The National Federation of Prostate Cancer Support Groups
Geplaatst door Europa Uomo – The European Prostate Cancer Coalition op woensdag 16 maart 2016
The German Cancer Society, the Bundesverband Prostatakrebs Selbsthilfe e.V. (BPS), the Förderverein Hilfe bei Prostatakrebs (FHbP) and OnkoZert participate in the multinational study.
Berlin 02.02.2016. The German Cancer Society announces participation in a multinational study for improvement of quality of life for patients with localized prostate cancer. The project „Prostate Cancer Outcomes ‒ Compare and Reduce Variation“ is financed with 3 million Australian dollars by the Movemeber Foundation and envolves hospitals from 10 countries.
The study will gather and compare patient reported quality of life information and clinical endpoints utilizing identical units of measure for reporting by each of the participating hospitals. Indicators employed in the study are already mostly utilized in the Prostate Cancer Centers certified by the German Cancer Society and are recommended by the International Consortiumfor Health Outcomes Measurement (ICHOM). The German Cancer Society will be responsible for coordinating the 24 hospitals in Germany participating in the study. Further partners in this project are the BPS, FHbP and the independent institute OnkoZert.
25 percent newly diagnosed male cancer patients have prostate cancer. Prostate cancer is one of the most frequent cancers in men in Germany and in many other countries. Possible treatment complications are incontinence, bowel irritation, erectile dysfunction and psychological problems. Significant differences in treatment results worldwide are being suspected. Recording them in the participating hospitals and in a central data repository of the study aims to provide transparency and explanations of differences in treatment quality.
Günter Feick, BPS and Günther Carl, FHbP underline the importance of this project:
„Studies about the quality of treatments for prostate cancer are mostly recording mortality data. Knowledge about quality of life reported by patients is scarce. Furthermore there are no international comparisons on health outcomes based upon a sizeable amount of data reported by a larger number of hospitals. Both aspects are taken into account by the Movember study and that is why we are supporting the study. We are convinced – measuring and comparing leads to improvement of treatments.“
Dr. Johannes Bruns, secretary general of the German Cancer Society emphasizes, „There are various efforts currently under way for improving the treatment of prostate cancer in Germany. One of them is the extensive PREFERE study comparing the various treatment modalities for the locally confined prostate cancer. The new project is complementing existing attempts – it will be condusive for better identification of key factors important for high quality health outcomes in the treatment of prostate cancer. I am pleased that we are having this opportunity offered by Movember to participate in this project.“
Paul Villanti, Director of Programmes Movember Foundation addressing this collaboration:
“We’re pleased to announce that we are working with the German Cancer Society and partners on this new project which enables us to expand this work into Germany.
We’re committed to the implementation of a set of national and international prostate cancer outcomes projects to better measure treatment and quality of care results.
Looking at these results between countries will offer an unprecedented opportunity to dramatically reduce variation in care and better understand what’s best for men with prostate cancer”
The German Cancer Society
The German Cancer society – a successor organization of the „Comité für Krebssammelforschung“ founded 1900 – is the largest scientifc organization for oncology in the german speaking community. The German Cancer Society encompasses more than 7.400 individual members in 24 work groups dedicated to research and treatment of cancer in addition to 16 federal state cancer societies and 35 supporting members.
The German Cancer Society is actively supporting evidence based cancer care, interdisciplinarity, consequent standards of treatment quality and is co-initiator of the National Cancer Plan. For more information see: www.krebsgesellschaft.de
The Movember Foundation
The Movember Foundation is a global charity committed to the improvement of men`s health. Movember finances innovative research and living with cancer support programs aiming towards helping men living a happier, healthier and longer life. The work of the Movember Foundation is supported by millions of people helping to fund over 1.000 projects in the interest of patients with prostate cancer, testicular cancer, poor mental illness and physical inactivity. Movember`s vision ist to take action for creating positive change in men’s health by raising awareness and educating men year-round.
For more information see: www.movember.com
The Bundesverband Prostatakrebs Selbsthilfe e. V. (BPS)
The BPS is a charitable organization of and for prostate cancer patients and there next of kin
with 237 patient support groups across Germany. The BPS operates under the auspices of the charitable foundation Deutsche Krebshilfe and is a member of the European Prostate Cancer Patient Coalition Europa UOMO.
For more information see: www.prostatakrebs-bps
|The Förderverein Hilfe bei Prostatakrebs (FHbP
The charitable organization FHbP was founded by members of the Bundesverband Prostatakrebs Selbsthilfe e.V. on 3 July 2014 at Magdeburg, is registered and based in Bonn. The FHbP aims to foster prostate cancer research, support men with prostate cancer and the BPS and strives to build a charitable foundation.
For more information see: http://fhbp.de
OnkoZert is an independent institute.serving the certification system of the German Cancer Society for organ specific cancer centers and comprehensive centers.
For more information see www.onkozert.de
Pressestelle der Deutschen Krebsgesellschaft e. V.
Dr. Katrin Mugele
Tel: +49 30 3229329-60
On this world cancer day the prostate cancer patient support organization of Germany (BPS) is bringing to mind the significance of certified prostate cancer centers.
Bonn, 2 February 2016 – every year 68.000 men are diagnosed with and 12.000 men are dying of prostate cancer in Germany. At the time of diagnosis men are 65 years of age on average. After the patients` trauma realizing to have cancer they are facing the questions – which are the best treatments for me and which is the best treatment facility. These important questions at the outset of a therapy motivate the BPS to allude once more to the merits of Prostate Cancer Centers certified by the Cancer Society of Germany www.krebsgesellschaft.de/gcs/german-cancer-society/certification.html
„This certification system is serving patients through high quality care and provide patients with orientation in a complex scenario of treatment opportunities. Certified Prostate Cancer Centers are conducting interdisciplinary tumor conferences attended by urologists, radiologist, oncologists and pathologists for defining the best treatment“, said Günter Feick, BPS chairman on Tuesday.
The Cancer Society of Germany certification system, including on site audits, are maintained by a commission of experts from all prostate cancer relevant professions, the independent institute OnkoZert and the BPS. Currently there are 94 certified Prostate Cancer Centers in Germany, 4 in Switzerland and 1 in Austria. They can be located via following German Cancer Society or BPS internet pages
For acquiring certification as Prostate Cancer Center hospitals must fulfill criteria specified by a commission with representatives from medical scientific associations, professional occupational organization for physicians and psychotherapists and the BPS. The criteria are based upon the medical guidline for treatment of prostate cancer and the requirements for interdisciplinary cooperation. Treatment results, health outcomes are reported annually and give information about the quality of oncological treatment. Deviations from pre-defined standards require explanations why certain treatments were not made available to patients.
These systematic evaluations provide an overview of the quality of care in general and assist Prostate Cancer Centers individually in comparing their performance with all other Prostate Cancer Centers.
The BPS is convinced that measuring and comparing will lead to improvements in care in any public health system. This is why the BPS stands up for a mandatory, nationwide quality measurement system. A necessary and basic step for achieving this goal was taken in Dec of 2016 through passing of the federal bill on hospital structures by the German parliament.
About the Bundesverband Prostatakrebs Selbsthilfe e.V. (BPS)
The BPS was founded in the year 2000 by 18 prostate cancer support groups and is headquartered in Bonn. Today the BPS is comprising of 237 support groups. The charitable organization operates under the auspices of the German Cancer Aid Foundation. The BPS represents the patients interests in the Federal Joint Committee www.english.g-ba.de and is a member of the European Prostate Cancer Patient Coalition UOMO.
For more information see: www.prostatakrebs-bps.de
Bundesverband Prostatakrebs Selbsthilfe e.V.
Vorstand gemäß §26 BGB:
Telefon: 0228 33889 504
Telefax: 0228 33889 510
The second edition of The Prostate Digest can now be downloaded in pdf format.
Please distribute this Prostate Digest to your individual members (by email or hard copy to those who doesn’t have an e-mail address). Any feedback (suggestions and comments) is welcome directly to our secretary, John Dowling, firstname.lastname@example.org.
Prostate cancer survivor and patient advocate Ken Mastris of Europa Uomo shares helpful techniques for identifying symptoms of advanced prostate cancer and making the most of your time at doctor’s appointments. Visit MenWhoSpeakUp.com to learn about a new program from Bayer HealthCare, inspired by eye-opening results from the International Prostate Cancer Symptoms survey. The program offers tools to help men with advanced prostate cancer speak up about symptoms they may be experiencing.
The European Medicines Agency (EMA) has launched a new webpage highlighting measures recommended by EMA to prevent medication errors for specific medicines. This page includes clear and easy-to-understand information for patients and healthcare professionals to further promote the safe use of medicines.
In order to promote the safe use of medicines, EMA will systematically communicate on any additional measure decided upon at EU level to prevent medication errors.
At the time of launch, the following communications are available:
- Compliance card to be given to patients using Farydak
- Guidance on prevention of medication errors with diabetes medicines containing insulin and a non-insulin active substance
- Guidance on prevention of medication errors with high-strength insulins
- EMA recommends measures to ensure safe and effective use of Strensiq
- Recommendations to prevent administration errors with Velcade (bortezomib)
In parallel, the EMA has published today a good practice guide on medication errors to improve the reporting, evaluation and prevention of medication errors by regulatory authorities and pharmaceutical industry throughout the EU.
Thousands of men with prostate cancer could benefit from a drug developed to combat ovarian cancer.
Olaparib, which was designed to fight cancers caused by inherited mutations, stopped tumour growth in a third of advanced prostate cancer patients.
The study, from the Institute of Cancer Research in London, is the first time that a genetically targeted drug has worked against prostate cancer.
Dr Iain Frame, director of research at Prostate Cancer UK, said: “Sometimes we find answers to research questions from unexpected sources.”
Olaparib was licensed last year for women with ovarian cancer and inherited BRCA mutations but is not yet approved for NHS patients by the National Institute for Health and Care Excellence or the Cancer Drugs Fund.
Read the full article at: http://www.thetimes.co.uk/tto/health/news/article4598932.ece